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Objective: To establish the abnormal title and the appropriate screening dilution for ANA 
(antinuclear antibodies) test by indirect immunofluorescence on HEp-2 cells (ANA HEp-2).
Methods: An analysis of ANA Hep-2 in serum samples from 126 healthy individuals was 
performed. The samples were screened at a dilution of 1:80, and those positive were di-
luted to the title of 1:5120. The abnormal title of ANA was defined as that corresponding 
to the 95th percentile of the test in this population. The sensitivity of the different titles of 
antinuclear antibodies was determined in a group of 136 patients with a diagnosis of auto-
immune rheumatic disease, and the specificity was determined in a group of 118 patients 
with other rheumatic diseases. The optimal cutoff value of the test was determined by ROC 
curve analysis.
Results: The frequency of ANA positivity in healthy subjects was 13.2%. There was no dif-
ference in the frequency of positive results according to gender or age. The abnormal title 
of ANA was defined as the dilution of 1:160. The 1:80 dilution had sensitivity of 87.7% and 
specificity of 67.8%, while the 1:160 dilution had sensitivity of 82% and specificity of 73.7%. 
By ROC curve analysis, a dilution of 1:160 corresponded to the optimal cutoff value.
Conclusion: The abnormal title and the optimal cutoff value of ANA HEp-2 in the population 
was 1:160. Therefore, the dilution of 1:160 is the optimal screening dilution, with better 
specificity but without significantly compromising the sensitivity of the diagnostic test.
© 2014 Elsevier Editora Ltda. All rights reserved.
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Detecção de anticorpos antinucleares por imunofluorescência indireta 
em células HEp-2: definindo a diluição de triagem adequada para o 
diagnóstico das doenças reumáticas autoimunes 
Palavras-chave:
Doença reumática autoimune
Anticorpos antinucleares
Imunofluorescência indireta
Valor de referência
r e s u m o
Objetivo: Definir o título anormal e a diluição de triagem adequada para o teste de FAN (fator 
antinúcleo) por imunofluorescência indireta em células HEp-2 (FAN HEp-2).
Métodos: Realizamos a pesquisa do FAN HEp-2 em amostras de soro de 126 indivíduos sau-
dáveis. As amostras foram triadas na diluição de 1:80, e aquelas positivas diluídas até o títu-
lo de 1:5120. O título anormal de FAN foi definido como aquele correspondente ao percentil 
95 do teste nesta população.  A sensibilidade dos diferentes títulos do FAN foi determinada 
em um grupo de 136 pacientes com diagnóstico de doença reumática autoimune, e a espe-
cificidade em um grupo de 118 pacientes com diagnóstico de outras doenças reumáticas. O 
valor de corte ótimo do teste foi determinado pelo estudo da curva ROC.
Resultados: A frequência de FAN positivo em indivíduos saudáveis foi de 13,2%. Não houve 
diferença na frequência de resultados positivos de acordo com o gênero ou a idade. O título 
anormal do FAN foi definido como a diluição de 1:160. A diluição dos soros de 1:80 apresen-
tou sensibilidade de 87,7% e especificidade de 67,8%, enquanto a diluição de 1:160 apresen-
tou sensibilidade de 82% e especificidade de 73,7%. Pela análise da curva ROC, a diluição de 
1:160 correspondeu ao valor de corte ótimo.
Conclusão: O título anormal e o valor de corte ótimo do FAN HEp-2 na população avaliada 
foram de 1:160. A diluição de 1:160 é, portanto, a  diluição de triagem ideal, com melhor espe-
cificidade, porém sem comprometimento significativo da sensibilidade diagnóstica do teste.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Antinuclear antibodies are important diagnostic markers of 
some autoimmune rheumatic diseases (AIRD), especially sys-
temic lupus erythematosus (SLE), Sjögren's syndrome (SS), sys-
temic sclerosis (SSc), dermatomyositis/polymyositis (DM/PM) 
and mixed connective tissue disease (MCTD).1,2
Known as antinuclear antibody (ANA), the test for anti-
nuclear antibodies by indirect immunofluorescence (IIF) is 
now called Research of Antibodies against Cellular Antigens 
(RACA-IIF), since it allows the detection of a range of anti-
bodies that react with antigens not only of the nucleus, but 
of the nucleolus, cytoplasm and cellular mitotic apparatus.3 
However, the term ANA continues to be widely used in clinical 
practice for historical reasons; so we will keep its use in this 
manuscript.
Thanks to its high diagnostic sensitivity, IIF using HEp-2 
cells as substrate is considered the gold standard method for 
research of ANA (ANA HEp-2).4 
However, a significant percentage of patients with various 
other autoimmune diseases, for which the test has no diag-
nostic value, can provide positive results in the test.1,2 Positive 
results can also occur in the context of infectious or neoplastic 
diseases, or even in individuals without clinical and laboratory 
evidence of autoimmune disease.5
The presence of ANA in an abnormal title is one of the cri-
teria for classification of SLE of the American College of Rheu-
matology (ACR).6 Recently, the Systemic Lupus International 
Collaborating Clinics (SLICC) Group reviewed and validated 
the ACR classification criteria, defining as one of the immuno-
logical criteria of SLE the presence of an ANA result above the 
laboratory reference value.7 However, neither ACR nor SLICC 
published specific recommendations about what procedures 
should be followed, for the establishment of ANA test abnor-
mal title or reference value. 
Different dilutions of serum screening, i.e., 1:40, 1:80 and 
1:160, have often been suggested as a cutoff value for ANA HEp-
2 test, without taking into account the recommendation of ACR 
with respect to the definition of ANA’s abnormal title.8-12
On the other hand, many manufacturers of commercial kits 
suggest that the test screening be made in the initial dilution of 
1:40, usually based on studies on healthy European or Ameri-
can populations.
In our country, a study showed that 12.9% of healthy indi-
viduals may have positive ANA HEp-2 in the title of 1:80 – the 
screening dilution used by many clinical laboratories, and a 
fact that reinforces the importance of establishing an appro-
priate screening dilution for the diagnosis of AIRD.13
The objective of this study is to determine, in a Brazilian 
population, the ANA test abnormal title, when performed by 
IIF on HEp-2 cells, by studying apparently healthy individuals; 
to determine the measures of test diagnostic accuracy, such as 
sensitivity, specificity, positive (LR+) and negative (LR-) likeli-
hood ratio, by studying a group of patients with AIRD and an-
other group with other rheumatic diseases, for which ANA has 
no diagnostic significance; and to establish the optimal cutoff 
value for the test with an analysis by ROC (Receiver Operating 
Characteristic) curve.
Materials and methods
Patients
Two distinct groups of patients were investigated:
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Group 1: To determine the sensitivity of ANA HEp-2, 139 pa-
tients with an established diagnosis of AIRD were evaluated, 
including 72 with SLE, 12 with SS, 31 with SSc (including lim-
ited and diffuse cutaneous forms, MCTD and the patterns over-
lapping with SLE, SS and PM), 10 with undifferentiated connec-
tive tissue disease (UCTD) and 14 with DM/PM, according to 
specific classification criteria.6,14-19
Group 2: To determine the specificity of ANA HEp-2, 118 pa-
tients with an established diagnosis of other rheumatic diseas-
es were evaluated, including 38 with rheumatoid arthritis (RA), 
17 with spondyloarthritis, 26 with systemic vasculitis, 10 with 
osteoarthritis, 23 with fibromyalgia and 4 with gout, according 
to specific classification criteria.20-24
For the determination of reference intervals in the clini-
cal laboratory, the Clinical and Laboratory Standards Institute 
(CLSI) recommends the assessment of at least 120 subjects 
considered healthy and the use of non-parametric statistical 
tests.25 Following the CLSI recommendations, 126 healthy sub-
jects living in the metropolitan region of Belo Horizonte, Minas 
Gerais, were evaluated, and matched according to gender and 
the following age groups: 18-30 years, 31-40 years, 41-50 years 
and 51-65 years.
Individuals aged between 18 and 65 years old, who were 
in full and regular practice of their work activities and did not 
present any physical or mental disabling condition, were con-
sidered as healthy subjects, according to the model proposed 
by Tan et al.8 The abnormal ANA HEp-2 title was defined as that 
corresponding to the 95th percentile of this population.26
All patients in groups 1 and 2 were recruited consecutively 
in the Service of Rheumatology, Hospital das Clínicas, Federal 
University of Minas Gerais, and Santa Casa de Belo Horizonte, 
Minas Gerais, Brazil, between September 2010 and September 
2011. All the subjects signed an informed consent, and then 
a sample of blood for centrifugation was obtained. After that, 
the resultant serum was aliquoted and stored at -80°C. The 
study was approved by the Ethics in Research Committees of 
the Federal University of Minas Gerais and Santa Casa de Belo 
Horizonte.
ANA HEp-2
Serum samples from all participants were analyzed for the 
presence of antibodies against cellular constituents by in-
direct immunofluorescence method, using slides with HEp-
2 cells, according to the manufacturer's recommendations 
(BION Enterprises, Des Plaines, IL, USA) and using 1:80 as 
screening dilution. The analyzes were performed by two ex-
perienced observers (blinded to the patients' diagnosis and 
to the result issued by the other colleague) in an epifluores-
cence microscope (Nikon Eclipse E400) at 400× magnification. 
The fluorescence patterns were classified according to recom-
mendations of the 3rd Brazilian Consensus for Research on 
Autoantibodies against Cellular Constituents - ANA HEp-2.3 
The samples were classified as positive when they showed 
fluorescence intensity equal to or greater than the positive 
control of minimal reactivity (1+/4+) in any cellular compart-
ment (nucleus, nucleolus, cytoplasm or mitotic apparatus). 
At the time of the screening, positive samples were succes-
sively diluted in phosphate buffered saline (PBS) to the titer of 
1:5120.  The final title was the one in which it was still possible 
to identify a well-defined morphological pattern, with mini-
mal fluorescence intensity. 
All cases with divergent results of title and/or fluorescence 
pattern were reviewed and ranked after consensus among ob-
servers.
Statistical analysis
Continuous variables with normal distribution were expressed 
as mean ± standard deviation, and those with non-parametric 
distribution were expressed as median and interquartile range. 
Categorical variables were presented as frequency and per-
centage. For analysis of categorical variables, we used the chi-
square (χ2) or Fisher's exact test. The level of statistical signifi-
cance was 5% (p <0.05). The study of interobserver agreement 
was conducted by kappa statistics. The sensitivity and speci-
ficity, with respective confidence intervals of 95%, were calcu-
lated as the percentage of positive results in group 1 patients 
and as the percentage of negative results in group 2 patients, 
respectively. LRs were calculated by analysis of the results of 
group 1 patients, both in comparison with the results of group 
2 and with those of healthy subjects. The discriminative abil-
ity of ANA HEp-2 was evaluated by ROC curve analysis in two 
distinct ways: as the ability to discriminate between patients in 
group 1 and in group 2, as well as among group 1 patients and 
healthy subjects. Through the study of ROC curve, the screen-
ing dilution of ANA HEp-2 with the best compromise between 
sensitivity and specificity (optimal cutoff value) was also estab-
lished. Statistical analysis was performed by Medcalc for Win-
dows, version 12.1.3 (Medcalc Software, Mariakerke, Belgium).
Results
The mean age of group 1 was 42 years (± 11.7), the proportion 
of female patients 88.5%, and the median for disease duration 
was 6.7 years (3.2-12.7 ). The mean age in group 2 was 50 years 
(± 13.8), the proportion of female patients 71.2%, and the me-
dian time after diagnosis was 5 years (2-10). The mean age of 
the healthy subjects was 39.7 years (± 10.8), and the proportion 
of female patients was 54%.
Initially, we evaluated the interobserver agreement for clas-
sifying samples as positive or negative at the time of screen-
ing, and observed that the concordance was good to very good 
(kappa = 0.783, CI95% 0.640-0.925). In a second step, we have 
studied the agreement with respect to the final title and the 
fluorescence pattern. The kappa statistics for the title was 0.762 
(linear weighted kappa, CI95% 0.681-0.844), and for the pattern 
was 0.894 (quadratic weighted kappa, CI95% 0.780-1.000), indi-
cating that the degree of agreement was good to very good.
Assuming a change in the definition of the title until ± 1 
dilution, the absolute agreement was 95.7%. Disagreements of 
definition between nuclear homogeneous and nuclear dense 
fine speckled patterns were the main cause of disagreement in 
the classification of fluorescence patterns.
Frequency of positive ANA in healthy population
Of 126 healthy subjects, 17 were positive for ANA HEp-2 
(13.5%) (Table 1), with no difference in frequency between fe-
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males and males (16.1% and 10.3% respectively, p = 0.489) or 
according to age (p = 0.888).
The distribution of titers in healthy subjects revealed a 
predominance of low titers (1:80 and 1:160), although 29.5% 
of positive results occurred in titers ≥ 1:320, considered mod-
erate to high (Table 1). The more prevalent fl uorescence pat-
terns were the nuclear fi ne speckled, present in 11 individuals 
(64.7%), and nuclear dense fi ne speckled, present in 3 subjects 
(17.6%) (Table 2).
Defi nition of abnormal ANA title
The 95th percentile of ANA HEp-2 in the healthy population 
corresponded to the dilution of 1:160.
Considering this dilution as the abnormal title and thus 
the reference value of ANA HEp-2, the frequency of posi-
tive test results in the group of healthy subjects decreased 
to 6.3%.
Sensitivity and specifi city of ANA HEp-2 
The sensitivity and specifi city of ANA HEp-2, calculated for 
each dilution situated between 1:80 and 1:5120, are detailed 
in Table 3.
As the prevalence and diagnostic signifi cance of ANA in 
the different AIRD are variable, the proportion of positive re-
sults of ANA HEp-2 was determined for each disease repre-
sented in groups 1 and 2 (Figs. 1 and 2).
Compared with the 1:80 dilution, the use of the dilution of 
1:160 as reference value for the test was accompanied by a re-
duction of sensitivity of ANA HEp-2, from 87.8% to 82.0%, and 
by an increase of specifi city, from 67.8% to 73.8%.
The decrease in sensitivity was due mainly to a reduction 
in test positivity in patients with SLE and DM/PM. But in the 
patients with SSc, SS and DITC, the sensitivity remained prac-
tically unchanged.
The sensitivity of ANA HEp-2 in patients with SLE was 
87.5%, considering the dilution of 1:80 as the reference value. 
A decreased sensitivity to 81.9% was observed when only the 
test results in abnormal titer (> 1:160) were defi ned as positive.
In patients with DM/PM, the use of the reference value 
of 1:160 resulted in a decrease of diagnostic sensitivity, from 
57.1% to 42.8%.
ROC curve analysis
The ROC curve analysis showed that the ANA HEp-2 test has a 
good performance to discriminate between group 1 and group 
2 diseases. The area under the curve was 0.835 ( CI95% 0.787-
0.884 , p < 0.0001 ) , and the dilution of 1:160 was the one with 
the best compromise between sensitivity and specifi city .
The use of the healthy subject population for determin-
ing the rate of false positive results of ANA HEp-2 resulted in 
better diagnostic performance of the test, with an area under 
the curve of 0.916 (CI95% 0.872-0.961, p < 0.0001). Also in this 
Fig. 1 – Proportion of positive results of ANA HEp-2 
by Group 1 disease, according to the title. Proportion 
calculated as the number of positive results considering 
the respective title as the cutoff value of the test, divided 
by the total number of patients with the disease. UCTD, 
undifferentiated connective tissue disease; DM/PM, 
dermatomyositis/polymyositis; SSc, systemic sclerosis; SLE, 
systemic lupus erythematosus; SS, Sjögren syndrome.
Table 1 – Percentage of positive results of ANA Hep-2 in 
126 healthy subjects, according to title.
Title
1:80 1:160 1:320 1:640
Number 17 8 5 2 
Percentagea 13.5% 6.3% 4% 1.6%
a Number of positive results considering the title as the cutoff value 
of the test, divided by the total number of healthy individuals.
Table 3 – Sensitivity and specifi city of ANA HEp-2, 
according to the title (CI95%).
Title Sensitivity Specifi city
1:80 87.7% (81.1-92.7) 67.8% (58.6-76.1)
1:160 82.0% (74.6-88.0) 73.7% (64.8-81.4)
1:320 74.8% (66.8-81.8) 80.5% (72.2-87.2)
1:640 57.6% (48.9-65.9) 85.6% (77.9-91.4)
1:1280 46.8% (38.3- 55.4) 95.8% (90.4-98.6)
1:2560 27.3% (20.1-35.5) 96.6% (91.5-99.1)
1:5120 18.7% (12.6-26.2) 98.3% (94.0-99.8)
Sensitivity: calculated as the number of patients in group 1 with 
positive results, divided by the total number of patients in the group.
Specifi city: calculated as the number of patients in group 2 with 
negative results, divided by the total number of patients in the group.
Table 2 – Distribution of fl uorescence patterns and ANA 
Hep-2 titles in 17 healthy subjects with a positive test.
Pattern Title Total
1:80 1:160 1:320 1:640
NFS 6 3 2 0 11 (64.7%)
NDFS 1 0 1 1 3 (17.6%)
Nucleolar 2 0 0 0 2 (11.8%)
Centromeric 0 0 0 1 1 (5.9%)
Total 9 (52.9%) 3 (17.6%) 3 (17.6%) 2 (11.9%) 17 (100%)
NFS, nuclear fi ne speckled; NDFS, nuclear dense fi ne speckled.
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population, the dilution of 1:160 was the one with the best 
compromise between sensitivity and specifi city.
As the titles of the ANA HEp-2 are an important param-
eter for the interpretation of test results, and consider-
ing that the high titers are more frequent in patients with 
AIRD, LRs specifi c for the different titles of ANA HEp-2 were 
calculated (Table 4).
Discussion
The use of IIF HEp-2 as a method of choice for the investi-
gation of ANA, the optimization of commercial kits for the 
detection of many autoantibodies of clinical importance, and 
the technological evolution of microscopes resulted in sig-
nifi cant increase in the sensitivity of this test. These factors, 
combined with the use of the test by many physicians with 
the objective of to exclude the diagnosis of AIRD in patients 
with nonspecifi c signs and symptoms, had the effect of re-
ducing the specifi city of ANA HEp-2, with the identifi cation 
of positive results in a signifi cant proportion of individuals 
without clinical evidence of AIRD.2,3,5
Several studies have investigated the frequency and dis-
tribution of titles and fl uorescence patterns of ANA Hep-2 in 
healthy subjects and in the general population.8,13,27-30 It is im-
portant to emphasize that different defi nitions were used in 
these studies to classify an individual as healthy or normal, 
besides different recruitment criteria.
Despite these conceptual disagreements, the frequency 
of ANA HEp-2 positivity in the healthy population was 13.5%, 
similar to that reported by studies conducted in Brazilian and 
in other populations, using different criteria of selection and 
defi nition of healthy individuals.8,13,27,28,29
In the study by Tan et al., the frequency of positive results 
of ANA Hep-2 in 125 healthy subjects, recruited by fi fteen in-
ternational reference centers in search of autoantibodies, was 
31.7% in the title of 1:40, 13.3% in the title of 1:80, 5% in the 
title of 1:160 and 3.3% in the title of 1:320.8
In the other hand, Mariz et al. considered as healthy only 
individuals without previous or current evidence of AIRD, 
chronic infection and neoplastic disease, with negative serol-
ogy for HIV, hepatitis B and C, and that were not under regular 
use of glucocorticoid, immunosuppressive, antimicrobial or 
anti-infl ammatory agents. Of the 918 individuals analyzed, 
13.3% were positive at a dilution of 1:80, 7% at a dilution of 
1:160, 6% at a dilution of 1:320, 4.4% at a dilution of 1:640 and 
2,1% at dilutions ≥ 1:1280.13
Studying an ethnically heterogeneous population sample 
of 4,754 U.S. civilian non-institutionalized individuals aged 
from 12 years and without employing any specifi c criteria of 
recruitment or exclusion, Satoh et al. found a frequency of 
ANA HEp-2 of 13.8% at a screening dilution of 1:80.27
Fernandez et al. investigated 500 Brazilian blood donors 
and found the following frequencies of positive results of 
ANA HEp-2: 22.6% at 1:40 dilution, 8% at 1:80 dilution, 3.4% at 
1:160 dilution and 1.4% at dilutions ≥ 1:320.28
In contrast to the results described above, none of the 100 
healthy blood donors from predominantly Caucasian ethnic-
ity in Copple et al. study showed ANA HEp-2 positivity in the 
screening dilution of 1:40.30
Such discrepancies in the prevalence of ANA may be a 
result of both genetic-environmental and sociodemographic 
Fig. 2 – Proportion of positive results of ANA HEp-2 
by Group 2 disease, according to the title. Proportion 
calculated as the number of positive results considering the 
respective title as the cutoff value of the test, divided by the 
total number of patients with the disease. RA, rheumatoid 
arthritis; SA, spondylarthritis; FIBRO, fi bromyalgia; OA, 
osteoarthritis; VASC, vasculitis.
Table 4 – Positive and negative likelihood ratios of different titles of ANA HEp-2, considering as “not ill” those patients in 
group 2 and the healthy population (CI95%).
Title GROUP 2 HEALTHY
LR+ LR- LR+ LR-
1:80 2.73 (2.4-3.1) 0.18 (0.1-0.3) 6.5 (15.9-7.1) 0.14 (0.08-0.3)
1:160 3.12 (2.7-3.6) 0.24 (0.2-0.4) 20.67 (19.0-22.5) 0.19 (0.07-0.5)
1:320 3.84 (3.4-4.4) 0.31 (0.2-0.5) 18.85 (17.0-20.9) 0.26 (0.1-0.6)
1:640 3.99 (3.4-4.7) 0.5 (0.3-0.8) 36.26 (31.4-41.9) 0.43 (0.1-1.7)
1:1280 11.04 (9.2-13.2) 0.56 (0.2-1.3)
1:2560 8.06 (6.1-10.6) 0.75 (0.3-2.0)
1:5120 11.04 (7.8-15.6) 0.83 (0.2-3.3)
LR+: number of positive results in group 1 patients, divided by the number of false-positive results in patients from group 2 or in healthy 
individuals.
LR-: number of false-negative results in group 1, divided by the number of negative results in group 2 patients or in healthy subjects.
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factors as technical ones. Differences between microscopes 
and commercial reagents, as well as the heterogeneity in the 
training of observers, confer high interlaboratory variability in 
the results of IIF HEp-2.31.32
Unlike other studies that showed a higher frequency of 
ANA HEp-2 positivity in females and older people, we found 
no differences in the frequency of ANA Hep-2 in healthy sub-
jects by gender or age, dispensing thus the necessity of using 
specific screening dilutions, according to these variables.26-28
It is possible that our findings may be explained by the 
small number of subjects with positive ANA in each gender 
and age extract, thus limiting the statistical power to detect 
significant differences between groups, as well as by the ab-
sence of septuagenarian or octogenarian subjects. However, 
Mariz et al. also found no significant differences in the preva-
lence of ANA according to gender or age.13
A small proportion of healthy subjects (18 subjects, 14.3%) 
consisted of health professionals such as physicians, lab 
technicians and nursing technicians. Despite some studies 
implying that this occupational profile constitutes a risk fac-
tor for presence of anti-dsDNA antibodies or ANA Hep-2 in 
high titers, especially for those handling blood samples from 
patients with SLE, only two individuals of that subgroup had 
a positive test, which makes it unlikely that the recruitment 
of healthy volunteers with this profile did result in some sort 
of bias.8,29,33
The distribution of the fluorescence patterns and of the 
titles of ANA HEp-2 was similar to that described by Mariz 
et al.13 The only exception was the occurrence of a nuclear 
centromeric speckled fluorescence pattern in a healthy indi-
vidual. In the Mariz et al. study, this occurrence was observed 
exclusively in patients with AIRD.
Following the determination of ACR and SLIC, and adopting 
the CLSI guidelines for the definition of reference intervals in 
the clinical laboratory, the present study established a dilution 
of 1:160 as abnormal title or reference value of ANA HEp-2.6,25 
Employing this dilution as a reference value for the test, the 
frequency of ANA in abnormal titers in SLE  patients was 81.9%. 
Even lower frequencies of HEp-2 ANA in abnormal titles, i.e., 
76.0%, can be observed in patients with established SLE.26
Besides not sacrificing the diagnostic sensitivity of the 
test, the use of the 1:160 dilution for an initial screening of 
autoantibodies produced a 53.0% reduction in the number of 
positive results of ANA Hep-2 in the healthy population. As 
probable benefits of increasing the specificity of the test, we 
can list: the reduction of the number of incorrect diagnoses 
and of therapeutic prescriptions potentially harmful to the 
patient, as well as the reduction of requests for additional ex-
ams and unnecessary referrals to the rheumatologist.
The screening dilution of the test and how the patients are 
recruited are factors that may influence the frequency of ANA 
positivity.26,34 We did a cross-sectional evaluation of patients 
with established SLE, comprising a heterogeneous group with 
respect to activity and duration of illness, ethnic composition 
and use of corticosteroids and immunosuppressants. There-
fore, it is important to emphasize that in all SLE patients with 
a positive ANA HEp-2 test, the disease was in remission only 
at a dilution of 1:80. As such, it is important to emphasize that 
in all SLE patients with a positive ANA HEp-2 test, the disease 
was in remission only at a dilution of 1:80.
By studying the ROC curve, the optimal cutoff value of 
ANA HEp-2 for both comparison groups evaluated (group 2 
and healthy subjects) was defined as the dilution of 1:160. 
Beck et al. analyzed by ROC curve the results from ANA HEp-
2 of 47 patients with SLE and 27 patients with other auto-
immune diseases, and also found a dilution of 1:160 as the 
optimal cutoff value of the test.35 However, in that study the 
use of dilution of 1:160 as the cutoff value was associated 
with a significant reduction in the diagnostic sensitivity of 
HEp-2 ANA for SLE.35 Moreover, in the study by Tan et al., 
only the dilution of 1:160 was able to adequately discrimi-
nate among normal subjects and patients with SSc, SLE and 
SS, with sensitivities of 87.0%, 95.0% and 74.0%, respectively, 
and a specificity of 95%.
There is great variability in the literature as for what 
screening dilution to be used in the ANA HEp-2 test; some 
authors suggest the 1:40 dilution and others suggest dilutions 
of 1:160 and 1:80.8-12 However, universally they recommend 
that only titers >1:160 should be considered positive or rele-
vant from a diagnostic point of view, due to its higher positive 
predictive value for AIRD and to the presence of specific au-
toantibodies. The titles ≤ 1:80 are considered indeterminate, 
because they usually do not have diagnostic significance and 
are not associated with presence of specific autoantibodies 
(anti-dsDNA and anti-ENA).8-12
Because this is a test for autoantibodies screening, posi-
tive ANA HEp-2 results must be complemented by ordering 
of specific autoantibodies. There is a well defined association 
between the titles of ANA HEp-2 and the probability of pres-
ence of specific autoantibodies.11,12 In this sense, González et 
al. suggested 1:160 as the ideal screening dilution for ANA 
HEp-2, since this dilution has the highest positive predictive 
value for presence of anti-dsDNA and anti-ENA antibodies, 
when compared with the lower dilutions, and without com-
promising the sensitivity of the test for the diagnosis of SLE.12
In the healthy population, the cutoff value of 1:80 was as-
sociated with LR+ > 5, which situates a diagnostic test as very 
useful. However, only from the dilution of 1:160 a LR+ > 10 was 
obtained, considered as able to significantly modify the post-
test probability of the disease. In the population of individuals 
with other rheumatic diseases, only the dilution of 1:1280 was 
associated to a LR+ > 5. In both populations, titles under 1:160 
showed LR- < 0.2, considered as very useful to exclude the 
diagnosis of AIRD.
Our study has some limitations. We evaluated only pa-
tients with an established diagnosis of AIRD. However, except 
in SLE, the immune profile of most patients with SSc, DITC, 
MD/MP and SS tends to be stable over time.37-39
The results of our work were obtained with slides from 
the same manufacturer. Although the frequency of positive 
results in the healthy population was similar to studies that 
used slides from other manufacturers or in house, there are 
important qualitative differences among the commercial 
HEp-2 slides.8,13,27-29
As a result of the lack of standardization with regard to cell 
culture conditions, type of fixative used (acetone, alcohol/ac-
etone), characteristics of the conjugate (polyvalent or specific 
IgG, fluorescein/protein ratio), etc., such differences produce 
significant inconsistencies in the reproduction of titles and 
fluorescence patterns, when analyzing the same sample of 
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serum on slides from different manufacturers (even with the 
use of a single microscope and the same observer).40
Finally, other factors of technical nature, such as the mi-
croscope, the lamp power and the observer experience, also 
contribute to the great interlaboratory variability of ANA HEp-
2 test.31,32 Thus, our findings cannot be extrapolated to other 
laboratories; it is advisable that each laboratory establish its 
own ANA abnormal title, analyzing healthy individuals from 
the local population and using their own instruments.
In conclusion, the dilution of 1:160 was defined as the ab-
normal title of ANA HEp-2 and as the optimal cutoff value 
of the test. Therefore, it is important to note that in situa-
tions where ANA is required outside of the clinical setting, 
with the main objective to exclude the presence of AIRD in 
patients with nonspecific clinical signs and symptoms, as has 
occurred in today's medical practice, and due to the high fre-
quency of positive results in healthy subjects, the reference 
value of 1:160 would bring the benefit of a significant reduc-
tion in the frequency of "false-positive" results without sig-
nificant loss of diagnostic sensitivity.
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